

3 September 2021

Not for release to US wire services or distribution in the United States

FINEOS SUCCESSFULLY COMPLETES INSTITUTIONAL PLACEMENT UPSIZED TO A\$70 MILLION

FINEOS Corporation Holdings PLC (ASX:FCL) is pleased to announce the successful completion of a fully underwritten institutional placement as announced on 2 September 2021 ("**Placement**"), raising approximately A\$70 million through the issue of approximately 16.3 million new fully paid CHES Depositary Interests over FCL ordinary shares ("**CDIs**"). The Placement was undertaken at an offer price of A\$4.30 per new CDI. The Placement price represents a 5.1% discount to FCL's closing price of A\$4.53 per CDI on 2 September 2021.

The Placement received strong support from both existing and new institutional security holders. As a result, FINEOS has upsize the Placement by A\$10 million to A\$70 million. The funds raised from the Placement will primarily be used to support FINEOS' opportunity pipeline and provide working capital and balance sheet support for planned R&D investments and organic and inorganic growth opportunities.

Michael Kelly, FINEOS' founder and CEO stated "We are very pleased with the level of support we have received from investors and would like to thank our security holders for their strong support of FINEOS as we continue to execute on our vision and strategy. The successful completion of the Placement signals a clear endorsement from the market of our overall strategy."

The new CDIs are expected to settle on 7 September 2021, with allotment expected to occur on 8 September 2021. New CDIs issued under the Placement will rank equally with existing FINEOS securities from the date of issue.

The CDIs will be issued under FCL's placement capacity in accordance with ASX Listing Rule 7.1.

Security Purchase Plan

As announced on 2 September 2021, FCL is also undertaking a non-underwritten security purchase plan ("**SPP**") to raise up to A\$5 million. Eligible securityholders with a registered address in Australia, France, Ireland and New Zealand will be invited to subscribe for up to A\$30,000 in additional CDIs at the same issue price as the Placement of A\$4.30 per CDI. New CDIs issued under the SPP will rank equally with existing FINEOS CDIs from the date of issue.

The terms and conditions of the SPP will be set out in an SPP Offer Booklet, which is expected to be despatched to eligible security holders by their preferred method of contact on 15 September 2021.

MA Moelis Australia Advisory Pty Limited and Macquarie Capital (Australia) Limited have acted as bookrunners and joint lead managers in respect of the Placement. Clayton Utz has acted as Australian legal adviser to FINEOS.

This notice has been authorised for release to the ASX by the Company's CFO.

Investor enquiries:

Orla Keegan, Head of Investor Relations

P: +353 87 379 4920

E: orla.keegan@FINEOS.com

About FINEOS

FINEOS (ASX:FCL) is a leading provider of core systems for life, accident and health insurance carriers globally with 7 of the 10 largest group life and health carriers in the US as well as 6 of the 10 largest life and health carriers in Australia. With employees and offices throughout the world, FINEOS continues to scale rapidly, working with innovative progressive carriers in North America, Europe, and Asia Pacific.

The FINEOS Platform provides customers full end to end core administration for group, voluntary and individual across life, accident, and health. The FINEOS Platform includes the FINEOS AdminSuite core product suite as well as add-on products, FINEOS Engage to support digital engagement and FINEOS Insight for analytics and reporting.

For more information, visit www.FINEOS.com

Not an offer of securities

This announcement has been prepared for publication in Australia and may not be released to US wire services or distributed in the United States. This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States or any other jurisdiction. Any securities described in this announcement have not been, and will not be, registered under the US Securities Act of 1933 and may not be offered or sold in the United States except in transactions exempt from, or not subject to, the registration of the US Securities Act and applicable US state securities laws.